Payment overview · 2025
General Payments
$737.07
39 reported records · 18 companies
Healthcare provider profile · identity verified
Manzar J Shafi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · HAGERSTOWN, MD · NPI 1689655367
Verified facts
What the public records show
CMS Open Payments records show Manzar J Shafi, M.D. received $737.07 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $146.19 | 19.8% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.78 | 12.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $76.03 | 10.3% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $49.18 | 6.7% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $47.06 | 6.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.43 | 5.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.25 | 5.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.11 | 4.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.17 | 4.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.21 | 4.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.81 | 3.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.76 | 3.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.28 | 2.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.02 | 2.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.88 | 2.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.80 | 2.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.51 | 2.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$13.60 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $737.07 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.06 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $65.84 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $62.69 | 4 | 2025 |
Source payment records
|
|||||
| CORE Normalized: core |
Device | Stryker Corporation | $49.18 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.71 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $47.06 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.43 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.20 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.20 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.25 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.25 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.25 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.11 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.83 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $30.21 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 373 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 317 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 99 |
| Metformin Hcl | Metformin Hcl | 297 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 92 |
| Lisinopril | Lisinopril | 258 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 64 |
| Losartan Potassium | Losartan Potassium | 192 | 62 |
| Furosemide | Furosemide | 190 | 66 |
| Omeprazole | Omeprazole | 179 | 56 |
| Famotidine | Famotidine | 158 | 43 |
| Potassium Chloride | Potassium Chloride | 149 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 48 |
| Simvastatin | Simvastatin | 143 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 135 | 41 |
| Gabapentin | Gabapentin | 119 | 43 |
| Ozempic | Semaglutide | 110 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 39 |
| Prednisone | Prednisone | 109 | 53 |
| Buspirone Hcl | Buspirone Hcl | 107 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 104 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 43 |
| Eliquis | Apixaban | 86 | 21 |
| Azithromycin | Azithromycin | 80 | 60 |
| Methylprednisolone | Methylprednisolone | 79 | 68 |
| Montelukast Sodium | Montelukast Sodium | 76 | 23 |
| Trazodone Hcl | Trazodone Hcl | 76 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 23 |
| Tramadol Hcl | Tramadol Hcl | 72 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 68 | 16 |
| Mounjaro | Tirzepatide | 68 | 15 |
| Clonidine Hcl | Clonidine Hcl | 67 | 21 |
| Mirtazapine | Mirtazapine | 64 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 19 |
| Glimepiride | Glimepiride | 59 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 19 |
| Meclizine Hcl | Meclizine Hcl | 57 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 11 |
| Januvia | Sitagliptin Phosphate | 55 | 16 |
| Sertraline Hcl | Sertraline Hcl | 55 | 15 |
| Topiramate | Topiramate | 55 | 15 |
| Meloxicam | Meloxicam | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | 13 |
| Ezetimibe | Ezetimibe | 49 | 16 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 47 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 46 | 12 |
| Allopurinol | Allopurinol | 45 | 14 |
| Divalproex Sodium | Divalproex Sodium | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 45 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Nifedipine Er | Nifedipine | 42 | 12 |
| Irbesartan | Irbesartan | 40 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 12 |
| Lorazepam | Lorazepam | 37 | 13 |
| Carvedilol | Carvedilol | 36 | 11 |
| Alprazolam | Alprazolam | 34 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 26 |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | 11 |
| Cephalexin | Cephalexin | 30 | 27 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 26 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | 11 |
| Cilostazol | Cilostazol | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Nystatin | Nystatin | 19 | 12 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Ketoconazole | Ketoconazole | 18 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Desloratadine | Desloratadine | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $737.07 · 39 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, CORE, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, INCEPTIV, INSPIRE, JARDIANCE, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, WaveWriter Alpha Prime 16, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error